Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy
Karl D. Lewis(University of Colorado Denver), Anjali Narwal(Regeneron (United States)), Melissa Mathias(Regeneron (United States)), K. Nunnink(Regeneron (United States)), Christina J. Perry(Florey Institute of Neuroscience and Mental Health), Kosalai Kal Mohan(Regeneron (United States)), Matthew G. Fury(Regeneron (United States)), Elizabeth Stankevich(Regeneron (United States)), S. Li(Regeneron (United States))
Cited by 3
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431